Insight: U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million

Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.

from Reuters: Money News https://ift.tt/2BsbOFi
via IFTTT

• Tweet
• Share
• Share
• Share
• Share